Lai TYY - Search Results

1

Ophthalmic Application of Anti-VEGF Therapy.

Lai TYY, Cheung CMG, Mieler WF. Lai TYY, et al. Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):479-480. doi: 10.22608/APO.2017500. Asia Pac J Ophthalmol (Phila). 2017. PMID: 29204994 Free article. No abstract available.

2

Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series.

Chan WM, Lam DS, Wong TH, Lai TY, Kwok AK, Tam BS, Li KK. Chan WM, et al. Ophthalmology. 2003 Dec;110(12):2395-402. doi: 10.1016/S0161-6420(03)00788-7. Ophthalmology. 2003. PMID: 14644724 Clinical Trial.

3

Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy.

Lai TY, Chan WM, Lam DS. Lai TY, et al. Am J Ophthalmol. 2004 May;137(5):826-33. doi: 10.1016/j.ajo.2003.11.079. Am J Ophthalmol. 2004. PMID: 15126146

4

Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.

Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS. Tong JP, et al. Am J Ophthalmol. 2006 Mar;141(3):456-62. doi: 10.1016/j.ajo.2005.10.012. Am J Ophthalmol. 2006. PMID: 16490490 Clinical Trial.

5

Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.

Chan WM, Lai TY, Liu DT, Lam DS. Chan WM, et al. Am J Ophthalmol. 2007 Jun;143(6):977-983. doi: 10.1016/j.ajo.2007.02.039. Epub 2007 Apr 24. Am J Ophthalmol. 2007. PMID: 17459318

6

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Chan WM, Lai TY, Liu DT, Lam DS. Chan WM, et al. Ophthalmology. 2007 Dec;114(12):2190-6. doi: 10.1016/j.ophtha.2007.03.043. Epub 2007 Jun 28. Ophthalmology. 2007. PMID: 17599414 Clinical Trial.

7

Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series.

Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS. Chan WM, et al. Retina. 2008 Jan;28(1):71-80. doi: 10.1097/IAE.0b013e31815e9339. Retina. 2008. PMID: 18185141

8

Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.

Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP. Chan WM, et al. Retina. 2008 Oct;28(9):1308-13. doi: 10.1097/IAE.0b013e31818358b2. Retina. 2008. PMID: 18728623

9

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, Li CL. Lam DS, et al. Retina. 2009 Mar;29(3):292-9. doi: 10.1097/IAE.0b013e31819a2d61. Retina. 2009. PMID: 19287286 Clinical Trial.

10

Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.

Lai TY, Chan WM, Liu DT, Lam DS. Lai TY, et al. Retina. 2009 Jun;29(6):750-6. doi: 10.1097/IAE.0b013e31819ed6bd. Retina. 2009. PMID: 19357555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters